Sarepta Therapeutics

Sarepta Therapeutics

Sarepta Therapeutics is a biopharmaceutical company founded by Marwan Fawaz in 1980 and headquartered in Cambridge, Massachusetts developing precision genetic medicines for the treatment of rare neuromuscular diseases.

Serepta Therepeutics, formerly AVI BioPharma, is a biotechnology company that is headquartered in Cambridge, Massachusetts, and was founded in 1980 by Marwan Fawaz. The company is developing gene therapies and medicines for the treatment of neuromuscular diseases such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy (LGMD), and Charcot-Marie-Tooth (CMT). Serepta Therapeutics creates their gene therapies and medicines using multiple therapeutic approaches which include RNA, gene therapy, and gene editing.

Partners

Timeline

1980

Sarepta Therapeutics was founded by Marwan Fawaz.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Amit Patel

Investor

Bo Cumbo

Senior Vice President & Chief Commercial Officer

Bruce Girton

Employee

Diane Berry

Vice President, Global Health Policy and Government Affairs

Douglas Ingram

President and CEO

Gary Charbonneau

Senior Vice President, Global Regulatory Affairs

Gilmore O'Neill

Senior Vice President, R&D and Chief Medical Officer

Ian Estepan

Chief of Staff, Vice President, Corporate Affairs

Jason Gatlin

Employee

Joan Nickerson

Vice President, Human Resources

Louise Rodino-Klapac

Vice President, Gene Therapy

Quinn Viens

Employee

Sagar Desai

Employee

Sandy Mahatme

Executive Vice President, CFO & CBO

Sarah Higgins

Employee

suchith nareddy

Employee

Ty Howton

Senior Vice president, General Counsel and Corporate Strategy

Further reading

Title
Author
Link
Type
Date

Sarepta Therapeutics enters manufacturing partnership for DMD treatment

Maggie Lynch

Web

Sarepta Therapeutics shares soar 50% on positive preliminary results for muscular dystrophy gene therapy

Angelica LaVito

News

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
July 2, 2020
FierceBiotech
Sarepta Therapeutics has secured a license to a drug that could enable more patients to receive its gene therapies. The deal grants Sarepta the exclusive right to use Hansa Biopharma's imlifidase to eliminate neutralizing antibodies in Duchenne muscular dystrophy and limb-girdle muscular dystrophy patients.
Mark Terry
June 9, 2020
BioSpace
On Monday, Sarepta Therapeutics announced positive results from a small study of SRP-9003, its gene therapy for limb-girdle muscular dystrophy Type 2E (LGMD2E).
BioSpace
June 8, 2020
BioSpace
-- In post-treatment muscle biopsies, clinical trial participants in the high-dose cohort showed a dose-dependent increase in transduction and expression when compared with the low-dose cohort, with a mean of 72% beta-sarcoglycan (beta-SG) positive fibers, as measured by immunohistochemistry (IHC), substantially exceeding the pre-defined 50% measure for success -- -- A mean signal intensity of 73% in the high-dose group was observed compared to normal control -- -- A mean beta-sarcoglycan
BioSpace
May 11, 2020
BioSpace
Agreement leverages Sarepta's leadership in gene therapy for neuromuscular and cardiovascular diseases and Dyno's CapsidMap artificial intelligence platform to design AAV vectors
Mark Terry
May 11, 2020
BioSpace
Dyno says that with its research-and-development and collaboration deals with biopharma companies, it is potentially eligible for more than $2 billion in upfront payments, research support, and various milestones and option fees.
Reuters Editorial
December 23, 2019
U.S.
Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.